Delamanid: a review of its use in patients with multidrug-resistant tuberculosis [J]. Drugs, 2015, 75(1): 91--100.Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015;75:91-100....
Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of res...
According to sources, the Central TB Division in the Ministry of Health and Family Welfare (MoHFW) has already asked state authorities to send their requirement of Delamanid based on the estimated patient load in the 6-17 age group. The patients in this age group cannot use Bedaquiline, anothe...
TOKYO--(BUSINESS WIRE)-- Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission has granted a marketing authorization for Deltyba™ (delamanid) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult pati...
Objectives: Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB. Methods...
Delamanid inhibits the synthesis of mycolic acid, an essential component of mycobacterial cell walls. Regulatory approval has been received in the EU, Japan, South Korea, Hong Kong, the Philippines, Turkey and India where it is marketed as Deltyba™. Delamanid is not yet approved for use in...
These results are reassuring and provide evidence of the safety of concurrent bedaquiline and delamanid use in patients with multidrug-resistant or rifampicin-resistant tuberculosis. We used a Data sharing Deidentified participant data and the data dictionary will be available on request, and on ...
This publication is intended to serve as a reference tool for countries with limited resources as they develop or revise national guidelines for the use of... LTU Politics Program - 《Geneva Switzerland Who》 被引量: 2309发表: 2006年 The Global Plan to Stop TB 2006-2015 PMCID: PMC2636638 ...
Since then, WHO has endorsed and gradually broadened indications for their use. In 2019, WHO recommended for the first time that bedaquiline should be used for treatment of all patients with MDR-TB. Delamanid is also recommended for treatment of MDR-TB, but is considered lower priority than ...
DelamanidEFFICACYSafetyObjectives The combined use of bedaquiline and delamanid(BDQ-DLM)is limited by an increased risk of prolonging the QTc interval.We retrospectively evaluated patients who received DLM/BDQcontaining regimens at a TB-specialized hospital.We aimed to present clinical effica...